AveXis, Inc. (NASDAQ:AVXS) has been given a $103.00 target price by Chardan Capital in a report released on Sunday. The brokerage presently has a “buy” rating on the stock. Chardan Capital’s target price points to a potential upside of 45.32% from the stock’s current price.

A number of other analysts have also weighed in on the company. BMO Capital Markets restated an “outperform” rating and issued a $95.00 target price on shares of AveXis in a research note on Friday. Citigroup Inc. set a $100.00 target price on AveXis and gave the company a “buy” rating in a research note on Thursday. Jefferies Group LLC restated a “buy” rating and issued a $92.00 target price on shares of AveXis in a research note on Thursday, May 25th. Finally, Goldman Sachs Group, Inc. (The) raised their target price on AveXis from $91.00 to $108.00 and gave the company a “buy” rating in a research note on Friday, March 17th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $87.86.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

AveXis (AVXS) traded up 2.166% during trading on Friday, hitting $72.415. 249,513 shares of the stock traded hands. AveXis has a one year low of $31.55 and a one year high of $85.98. The stock’s market cap is $2.01 billion. The company has a 50-day moving average price of $74.51 and a 200 day moving average price of $65.13.

AveXis (NASDAQ:AVXS) last issued its quarterly earnings data on Thursday, May 11th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.94) by $0.13. During the same quarter in the prior year, the company earned ($1.24) earnings per share. Analysts expect that AveXis will post ($4.41) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “AveXis, Inc. (AVXS) Given a $103.00 Price Target at Chardan Capital” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/06/19/avexis-inc-avxs-given-a-103-00-price-target-at-chardan-capital.html.

In related news, VP Sukumar Nagendran sold 1,780 shares of AveXis stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $81.39, for a total value of $144,874.20. Following the completion of the sale, the vice president now directly owns 1,780 shares in the company, valued at $144,874.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders sold 5,341 shares of company stock valued at $406,682.

Hedge funds have recently made changes to their positions in the company. VHCP Management II LLC purchased a new stake in shares of AveXis during the first quarter worth approximately $24,501,000. Geode Capital Management LLC purchased a new stake in shares of AveXis during the first quarter worth approximately $1,490,000. Goldman Sachs Group Inc. purchased a new stake in shares of AveXis during the first quarter worth approximately $1,795,000. Pictet Asset Management Ltd. purchased a new stake in shares of AveXis during the first quarter worth approximately $536,000. Finally, State Street Corp purchased a new stake in shares of AveXis during the first quarter worth approximately $1,058,000. Hedge funds and other institutional investors own 90.47% of the company’s stock.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.